Trial Updates

Phase II study of NE3107 in degenerative dementias

Boosting neurogenesis with NA-831: Phase III trial update

Potential clinical meaningfulness of donanemab data

Topline donanemab results: most positive Phase III data to date

Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials

Use of AD blood-based biomarkers for trial enrolment

Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials

TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease

Gotcha! A therapy app for proper name anomia in dementia

Lecanemab: a review

Lecanemab: drawbacks to consider

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

New pivotal study using photobiomodulation in Alzheimer’s treatment

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk